9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

 

Archive

Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed

Condition Malignant Mesothelioma Estimated Enrollment: 25 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Primary Purpose: Treatment Study ID Numbers: EORTC-08992 Study First Received: January 28, 2000 Last Updated: July 17, 2012 Estimated Primary Completion Date: June 2001 Primary Outcome Measures: Sponsors and Collaborators: European Organisation for Research and Treatment of Cancer - EORTC Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00004254...

Continue reading

Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

Condition Malignant Mesothelioma Estimated Enrollment: 69 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: NCCTG-N0021|CDR0000068659 Study First Received: June 6, 2001 Last Updated: December 5, 2016 Estimated Primary Completion Date: August 2004 Primary Outcome Measures: time to progression|survival|quality of life Sponsors and Collaborators: Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00017186...

Continue reading

Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 141 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: 07-091 Study First Received: December 10, 2007 Last Updated: January 19, 2017 Estimated Primary Completion Date: November 2011 Primary Outcome Measures: To establish the maximally tolerated dose (MTD) of intraoperative Intrathoracic/Intraperitoneal hyperthermic gemcitabine and cisplatin combination modulated by amifostine and sodium thiosulfate in patients with malignant pleural mesothelioma.|To determine and quantitate the safety of this combination in these patients by defining the dose limiting toxicity.|To study the pharmacokinetics of gemcitabine and cisplatin combination administered in...

Continue reading

Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura

Condition Malignant Mesothelioma Estimated Enrollment: 256 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Primary Purpose: Treatment Study ID Numbers: EORTC-08983 Study First Received: March 7, 2000 Last Updated: July 17, 2012 Estimated Primary Completion Date: January 2003 Primary Outcome Measures: Sponsors and Collaborators: European Organisation for Research and Treatment of Cancer - EORTC Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00004920...

Continue reading

Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma

Condition Malignant Mesothelioma Estimated Enrollment: 840 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Primary Purpose: Treatment Study ID Numbers: BTS-MRC-MS01|CDR0000347461|ISRCTN54469112|EU-20349 Study First Received: January 9, 2004 Last Updated: August 6, 2013 Estimated Primary Completion Date: null Primary Outcome Measures: Overall survival|Palliation of chest pain, breathlessness, malaise (e.g., feeling weak, tiredness, anorexia), and sweating attacks|Performance status as measured by WHO grade|Analgesic usage|Toxicity as measured by the NCIC CTC|Quality of life as assessed by the European Organization for Research and Treatment of Cancer|Tumor response as measured by the RECIST criteria|Progression-free survival as measured by CT scan Sponsors and Collaborators: Medical Research Council|National Cancer Institute (NCI) Result...

Continue reading

Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

Condition Malignant Mesothelioma Estimated Enrollment: 6 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CDR0000066157|P30CA006927|FCCC-96087|NCI-G98-1401 Study First Received: November 1, 1999 Last Updated: April 16, 2013 Estimated Primary Completion Date: December 1999 Primary Outcome Measures: Sponsors and Collaborators: Fox Chase Cancer Center|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00003263...

Continue reading

SU5416 in Treating Patients With Malignant Mesothelioma

Condition Malignant Mesothelioma Estimated Enrollment: 45 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: NCI-2012-02351|UCCRC-10409|UCCRC-NCI-44|NCI-44|CDR0000068023 Study First Received: July 5, 2000 Last Updated: May 31, 2013 Estimated Primary Completion Date: February 2007 Primary Outcome Measures: Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00006014...

Continue reading

Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery

Condition Malignant Mesothelioma Estimated Enrollment: 60 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Primary Purpose: Treatment Study ID Numbers: CDR0000564058|COL-ALIMESO|INCA-RECF0441|COL-2006-04 Study First Received: October 5, 2007 Last Updated: May 14, 2011 Estimated Primary Completion Date: May 2011 Primary Outcome Measures: Individual dosage-adapted protocol|Relationship between pharmacokinetic and pharmacodynamic parameters|Pharmacokinetics|Pharmacogenetic variations (MTHFR, TS, GSTpi, ERCC1, XPD) Sponsors and Collaborators: Centre Oscar Lambret|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00541073...

Continue reading

Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery

Condition Malignant Mesothelioma Estimated Enrollment: null Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Primary Purpose: Treatment Study ID Numbers: 99-085|CDR0000067791|CWRU-LILY-1599|LILLY-H3E-MC-JMCH(a)|NCI-G00-1767 Study First Received: May 2, 2000 Last Updated: June 17, 2013 Estimated Primary Completion Date: November 2000 Primary Outcome Measures: Sponsors and Collaborators: Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00005636...

Continue reading

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

Condition Pleural Malignant Mesothelioma Estimated Enrollment: 14 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Primary Purpose: Treatment Study ID Numbers: UPCC 03510 Study First Received: April 27, 2010 Last Updated: December 14, 2015 Estimated Primary Completion Date: October 2012 Primary Outcome Measures: 3-month PFS rate|Estimate the distribution of progression-free and over survival Sponsors and Collaborators: Abramson Cancer Center of the University of Pennsylvania Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01112293...

Continue reading